Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Medulloblastoma
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Trial Timeline
Apr 4, 2022 → Sep 30, 2027
NCT ID
NCT04743661About Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics
Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics is a phase 2 stage product being developed by Brain Biotech for Recurrent Medulloblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT04743661. Target conditions include Recurrent Medulloblastoma, Recurrent Ependymoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04743661 | Phase 2 | Active |
Competing Products
20 competing products in Recurrent Medulloblastoma